Article

Management of ocular inflammation and pain using novel insert

ICMYI: Dr. Tyson shares his pearls using the dexamethasone 0.4 mg insert (Dextenza, Ocular Therapeutix).

Sydney Tyson, MD, shares the take-home message from the presentation he delivered at the 2019 American Society of Cataract and Refractive Surgery meeting: "Management of Ocular Inflammation and Pain Following Cataract Surgery with Dexamethasone 0.4 mg Insert (Dextenza, Ocular Therapeutix)."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
At the 2025 American Society of Cataract and Refractive Surgery (ASCRS) meeting, Seth Pantanelli, MD, speaks about the EyHance and enVista IOLs. Dr. Pantanelli is a professor of ophthalmology at Penn State College of Medicine in Hershey, Pennsylvania.
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
© 2025 MJH Life Sciences

All rights reserved.